Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Kaya Miah"'
Autor:
Hans Salwender, Niels Weinhold, Axel Benner, Kaya Miah, Maximilian Merz, Mathias Haenel, Christian Jehn, Elias Mai, Ekaterina Menis, Igor Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Steffen Luntz, Britta Besemer, Markus Munder, Peter Brossart, Bertram Glass, Hans-Walter Lindemann, Katja Weisel, Christine Hanoun, Paul Schnitzler, Sarah Klemm, Hartmut Goldschmidt, Marc Raab, Ahmet Elmaagacli
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
ABSTRACTObjectives The seroprevalence of antibodies against Cytomegalovirus (CMV) is an established poor prognostic factor for patients receiving an allogeneic stem cell transplantation. However, the impact of CMV serology on outcome after autologous
Externí odkaz:
https://doaj.org/article/29275ba759c143408d4a11bc8678e7fb
Autor:
Elias K. Mai, Stefanie Huhn, Kaya Miah, Alexandra M. Poos, Christof Scheid, Katja C. Weisel, Uta Bertsch, Markus Munder, Oscar Berlanga, Dirk Hose, Anja Seckinger, Anna Jauch, Igor W. Blau, Mathias Hänel, Hans J. Salwender, Axel Benner, Marc S. Raab, Hartmut Goldschmidt, Niels Weinhold
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. We included 480 transplant-eligible newly-diagnosed multiple myeloma (MM) patients from the GMMG-MM5 trial (EudraCT No. 2010-019173-16) a
Externí odkaz:
https://doaj.org/article/1275a2059f114b41a54bedff8ec0c75f
Autor:
Lukas John, Kaya Miah, Axel Benner, Elias K. Mai, Katharina Kriegsmann, Michael Hundemer, Dorothee Kaudewitz, Carsten Müller-Tidow, Karin Jordan, Hartmut Goldschmidt, Marc S. Raab, Nicola Giesen
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionInfections are a leading cause of morbidity and mortality in patients with multiple myeloma (MM). MethodsTo examine the effects of modern second-generation novel agent therapy on immune cell subsets, in particular CD4+-T-cells, and infect
Externí odkaz:
https://doaj.org/article/1187c6ea9da8479ca823052df06d2766
Autor:
Janhavi R. Raut, Ben Schöttker, Bernd Holleczek, Feng Guo, Megha Bhardwaj, Kaya Miah, Petra Schrotz-King, Hermann Brenner
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-9 (2021)
Appropriate risk models could facilitate risk stratification for colorectal cancer (CRC) screening. Here, the authors propose a blood-based microRNA signature observed to have altered expression in pre-diagnostic samples, which might be useful to ide
Externí odkaz:
https://doaj.org/article/97aba233baf54954976d93d4bfb0339e
Autor:
Janhavi R. Raut, Megha Bhardwaj, Tobias Niedermaier, Kaya Miah, Petra Schrotz-King, Hermann Brenner
Publikováno v:
Cells, Vol 11, Iss 15, p 2462 (2022)
We recently derived and validated a serum-based microRNA risk score (miR-score) which predicted colorectal cancer (CRC) occurrence with very high accuracy within 14 years of follow-up in a large population-based cohort. Here, we aimed to assess and c
Externí odkaz:
https://doaj.org/article/274df9e90c094d5fac8348602aba96cc
Autor:
Nicola Giesen, Manik Chatterjee, Christof Scheid, Alexandra M. Poos, Britta Besemer, Kaya Miah, Axel Benner, Nicole Becker, Thomas Moehler, Ivana Metzler, Cyrus Khandanpour, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill, K. Martin Kortüm, Carsten Müller-Tidow, Gunhild Mechtersheimer, Benjamin Goeppert, Albrecht Stenzinger, Niels Weinhold, Hartmut Goldschmidt, Katja Weisel, Marc S. Raab
Publikováno v:
Blood. 141:1685-1690
Activating BRAF mutations are found in a small subset of patients with newly diagnosed multiple myeloma, but prevalence increases in late-stage, refractory disease, and the mutations are associated with adverse outcome. This prospective single-arm, o
Autor:
Nicola, Giesen, Manik, Chatterjee, Christof, Scheid, Alexandra M, Poos, Britta, Besemer, Kaya, Miah, Axel, Benner, Nicole, Becker, Thomas, Moehler, Ivana, Metzler, Cyrus, Khandanpour, Andrea, Seidel-Glaetzer, Karolin, Trautmann-Grill, K Martin, Kortüm, Carsten, Müller-Tidow, Gunhild, Mechtersheimer, Benjamin, Goeppert, Albrecht, Stenzinger, Niels, Weinhold, Hartmut, Goldschmidt, Katja C, Weisel, Marc S, Raab
Publikováno v:
Blood.
Activating BRAF mutations are found in a small subset of patients with newly diagnosed multiple myeloma but prevalence increases in late stage, refractory disease, and are associated with adverse outcome. This prospective single-arm, open-label, mult
Autor:
Elias K. Mai, Stefanie Huhn, Kaya Miah, Alexandra M. Poos, Christof Scheid, Katja C. Weisel, Uta Bertsch, Markus Munder, Oscar Berlanga, Dirk Hose, Anja Seckinger, Anna Jauch, Igor W. Blau, Mathias Hänel, Hans J. Salwender, Axel Benner, Marc S. Raab, Hartmut Goldschmidt, Niels Weinhold
Publikováno v:
Blood cancer journal. 13(1)
Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. We included 480 transplant-eligible newly-diagnosed multiple myeloma (MM) patients from the GMMG-MM5 trial (EudraCT No. 2010-019173-16) and perfor
Autor:
Stephan Fuhrmann, Peter Brossart, Markus Munder, Mathias Hänel, Anja Seckinger, Katja Weisel, Hartmut Goldschmidt, Helga Bernhard, Jan Dürig, Anna Jauch, Martin Goerner, Christina Kunz, Hans-Walter Lindemann, Steffen Luntz, Ahmet H. Elmaagacli, Igor Wolfgang Blau, Hans Salwender, Maximilian Merz, Sandra Sauer, Marc S. Raab, Martin Hoffmann, Elias K. Mai, Kaya Miah, Axel Benner, Dirk Hose, Uta Bertsch, Christof Scheid
Publikováno v:
Leukemia
Intensive upfront therapy in newly-diagnosed multiple myeloma (MM) including induction therapy (IT), high-dose melphalan (MEL200), and autologous blood stem cell transplantation (ASCT) followed by consolidation and/or maintenance is mostly restricted
Autor:
Axel Benner, Stephan Fuhrmann, Igor Wolfgang Blau, Martin Goerner, Uta Bertsch, Steffen Luntz, Markus Munder, Elias K. Mai, Katja Weisel, Ahmet H. Elmaagacli, Maximilian Merz, Sandra Sauer, Marc S. Raab, Hartmut Goldschmidt, Kaya Miah, Hans Salwender, Mathias Hänel, Christina Kunz, Anna Jauch, Jan Dürig, Christof Scheid, Anja Seckinger, Dirk Hose, Hans-Walter Lindemann, Peter Brossart, Helga Bernhard, Martin Hoffmann
The article Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age, written by Elias K. Mai, Kaya Miah, Uta Bertsch, Jan Dürig, Christof Scheid, Katja C. Weisel, Christina Kunz, Markus Munder, H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::683fb2bdb48b3c1b3cb39211af9e1813
https://hdl.handle.net/20.500.14017/d95b8682-3f21-444c-a851-40ea53cb6c03
https://hdl.handle.net/20.500.14017/d95b8682-3f21-444c-a851-40ea53cb6c03